Expert Interview
Discussing the development landscape of treatments for Congenital Hyperinsulinism (CHI) specifically: CRN04777, RZ358, and Avexitide.
Ticker(s): CRNX, RZLT, EIGRInstitution: Cook Children's Medical Center
- Director of Cook Children's Endocrinology department and former Clinical director of the Congenital Hyperinsulinism Center at the Children's Hospital of Philadelphia.
- Leads one of the first programs in the nation, Cook Children's Hyperinsulinism Center, applying a specialized team approach to treat hyperinsulinism
- Runs a hyperinsulinism clinic with ~130 patients with genetic forms of hyperinsulinism, 70-80 patients with transient forms of hyperinsulinism, and patients with syndrome and insulinoma.
- Knowledgeable about CRN04777, RZ358, and Avextide and is involved in developing studies for 2 of those 3 drugs.
Please describe your clinical practice. Roughly how many patients with Congenital Hyperinsulinism do you currently manage?
Added By: sara_adminWhat are your initial thoughts on the literature to date for these therapeutics?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited), how would you rate your level of excitement for these drugs?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
